Delivery Order SPE2DB22D1202-SPE2DB25FVHH2
Award Date 8/13/25
Potential Completion Date 8/14/25
Potential Value $4.3K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,621.24 for Zepbound 5 mg/0.5 mL pens on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, representing the...
- The Defense Logistics Agency awarded a $33,127.32 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors. This non-set-aside competitive award is scheduled for completion by August 20, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication indicated for weight management, reflecting the federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pens valued at $1,313.30. This firm fixed price delivery order, which will be completed by August 27, 2025, represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government. The award is classified as a non-set-aside procurement and was performed at the company's corporate office...
- The Defense Logistics Agency awarded a $15,525.98 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injections on August 4, 2025, with completion targeted for August 5, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $19,897.15 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on September 10, 2025, with an ultimate completion date of September 11, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist medication used...
- The Defense Logistics Agency awarded a $2,045.91 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract is structured as a firm fixed price delivery order with an ultimate completion date of August 11, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Zepbound is a diabetes and weight management medication, reflecting...
- The Defense Logistics Agency awarded a $9,266.86 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injections. This is a firm fixed price, competitively awarded contract with a completion date of September 3, 2025, and no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management,...
- The Defense Logistics Agency awarded a delivery order valued at $11,544.28 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens on July 29, 2025, with completion targeted for July 30, 2025. This firm fixed-price delivery order, which utilizes no set-aside designation, supports federal medical procurement needs and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound represents a specialized pharmaceutical...
- The Defense Logistics Agency awarded a $12,414.97 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injections on July 31, 2025, with an ultimate completion date of August 1, 2025. This firm fixed-price contract represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management in patients with obesity or overweight conditions,...
- The Defense Logistics Agency awarded a $10,165.63 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors with an ultimate completion date of June 2, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government, with performance to be fulfilled from the contractor's Conshohocken, Pennsylvania location....